| 2026-08-14 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-13 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-13 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-13 | Press release | Nektar Therapeutics Announces Second Quarter 2026 Financial Results |
| 2026-08-13 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-28 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-28 | Press release | Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U |
| 2026-07-24 | Press release | Press release · Jul 2026 |
| 2026-07-24 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-21 | Press release | Press release · Jul 2026 |
| 2026-07-21 | Press release | Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldes |
| 2026-06-26 | Press release | Press release · Jun 2026 |
| 2026-06-26 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-03 | Press release | Press release · Jun 2026 |
| 2026-06-03 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-27 | Press release | Press release · May 2026 |
| 2026-05-27 | Press release | Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York |
| 2026-05-08 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-08 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-07 | Press release | Nektar Therapeutics Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-01 | Press release | Press release · May 2026 |
| 2026-05-01 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-28 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-28 | Press release | Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-23 | Press release | Press release · Apr 2026 |
| 2026-04-23 | Press release | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option |
| 2026-04-23 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-21 | Press release | Press release · Apr 2026 |
| 2026-04-21 | Press release | Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering |
| 2026-04-20 | Deck | Analyst and Investor Event with Alopecia Areata Experts Presentation |
| 2026-04-20 | Press release | Press release · Apr 2026 |
| 2026-04-20 | Press release | Press release · Apr 2026 |
| 2026-04-20 | Press release | Nektar Therapeutics Announces Proposed Public Offering |
| 2026-04-20 | Press release | 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Sev |
| 2026-04-20 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-20 | 8-K | Form 8-K, Item 7.01 |